NNE Pharmaplan A/S – Trademark Portfolio

Entity Type: 03

NNE Pharmaplan A/S holds 5 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 5 filings in this category. The portfolio also extends into Class 35 (Advertising & Business) across 5 Nice Classification classes.

Vandtårnsvej 108-110

DK-2860 Soborg

5 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

NNE Pharmaplan A/S's trademark portfolio spans 5 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

42
Computer & Scientific (5 filings)

Scientific and technological services; industrial analysis and research services

35
Advertising & Business (4 filings)

Advertising; business management; business administration; office functions

37
Building & Construction (4 filings)

Building construction; repair; installation services

36
Insurance & Financial (4 filings)

Insurance; financial affairs; monetary affairs; real estate affairs

41
Education & Entertainment (2 filings)

Education; providing of training; entertainment; sporting and cultural activities

Frequently Asked Questions

How many trademarks does NNE Pharmaplan A/S have?

NNE Pharmaplan A/S has 5 U.S. trademarks filed with the USPTO.

What trademark classes does NNE Pharmaplan A/S file in?

NNE Pharmaplan A/S files trademarks across 5 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 35 (Advertising & Business), Class 37 (Building & Construction), Class 36 (Insurance & Financial), Class 41 (Education & Entertainment). Class 42 covers scientific and technological services; industrial analysis and research services.

What is NNE Pharmaplan A/S's trademark registration success rate?

NNE Pharmaplan A/S has a 0% trademark registration rate, with 0 out of 3 resolved applications resulting in successful registration. Currently, 0 applications are pending review.